Company Overview
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +895.13% |
| 6 Months: | +89.74% |
| 3 Months: | +107.15% |
| 1 Month: | +172.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KOD Kodiak Sciences Inc. R2KR3KPHARMA | 85.78 | -20.47 | $5.39B | 0.00% | -76.60% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 59.07M | 55.51M | 62.35M | 57.45M | 59.78M |
| Operating Income | -5.04M | -6.74M | -3.98M | -9.76M | -5.55M | -5.09M | -6.38M | -9.36M | -8.46M | -11.81M | -12.73M | -16.18M | -25.72M | -26.78M | -36.66M | -46.84M | -50.56M | -55.91M | -67.53M | -93.05M | -95.77M | -92.07M | -79.48M | -74.61M | -84.83M | -54.50M | -46.05M | -47.98M | - | - | -59.07M | -55.51M | -62.35M | -57.45M | -59.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -52.34M | -48.97M | -55.81M | -46.52M | -53.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -57.46M | -54.31M | -61.46M | -56.74M | -58.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.04M | -6.74M | -4.58M | -11.57M | -8.92M | -7.41M | -10.45M | -14.66M | -7.98M | -11.38M | -12.38M | -15.62M | -24.39M | -26.00M | -36.12M | -46.58M | -50.45M | -55.85M | -67.53M | -93.17M | -95.71M | -90.63M | -77.04M | -70.78M | -80.19M | -50.01M | -43.04M | -45.12M | - | - | -57.46M | -54.31M | -61.46M | -56.74M | -58.16M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.08 | -1.30 | - | -1.83 | -1.74 | -1.47 | -1.35 | -1.53 | -0.95 | -0.82 | -0.86 | - | - | -1.09 | -1.03 | -1.16 | -1.04 | -0.94 |
| R&D Expense | - | - | 3.15K | - | 3.64M | 3.59M | 4.71M | - | 5.72M | 8.84M | 10.12M | - | 20.17M | 20.56M | 29.31M | - | 40.34M | 45.40M | 56.00M | - | 76.18M | 73.74M | 61.68M | 56.52M | 66.96M | 36.19M | 29.93M | 32.51M | 31.88M | - | 43.64M | 42.76M | 50.48M | - | 48.55M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 341.38M | 277.32M | 186.85M | 234.39M |
| Operating Income | -17.15M | -25.52M | -26.37M | -49.19M | -136.01M | -267.05M | -341.38M | -277.32M | -186.85M | -234.39M |
| EBITDA | - | - | - | - | - | - | -322.80M | -234.53M | -149.50M | -203.65M |
| Interest Expense | - | - | - | - | - | - | 18.00K | 13.00K | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | -333.82M | -260.49M | -176.21M | -229.97M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - |
| Net Income | -17.13M | -27.94M | -41.44M | -47.37M | -133.10M | -266.99M | -333.82M | -260.49M | -176.21M | -229.97M |
| Diluted EPS | - | - | - | - | -2.91 | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 |
| R&D Expense | 14.05M | 22.02M | 18.79M | 37.51M | 107.39M | 217.34M | 267.59M | 206.30M | 126.09M | 182.37M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.24M | 92.19M | 358.87M | 1.07B | 904.22M | 666.63M | 479.37M | 335.58M | 351.53M |
| Total Equity | -24.24M | -41.08M | -68.74M | 86.83M | 345.36M | 860.75M | 663.32M | 436.17M | 265.78M | 150.29M | 157.38M |
| Cash & Equivalents | - | 9.62M | 1.40M | 88.25M | 211.80M | 944.40M | 731.51M | 190.43M | 285.51M | 168.07M | 209.86M |
| Total Liabilities | - | - | 21.96M | 5.36M | 13.51M | 206.60M | 240.90M | 230.46M | 213.59M | 185.29M | 194.15M |
| Current Liabilities | - | - | 9.16M | 4.83M | 11.71M | 31.42M | 64.68M | 52.50M | 41.73M | 25.57M | 45.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.05M | -17.66M | -29.03M | -39.15M | -83.43M | - | -206.46M | -154.18M | -117.32M | -136.01M |
| Investing Cash Flow | -771.00K | -209.00K | -581.00K | -137.00M | 104.83M | - | -336.51M | 249.23M | -755.00K | -506.00K |
| Financing Cash Flow | -120.00K | 9.64M | 116.47M | 299.69M | 717.38M | - | 1.90M | 31.00K | 501.00K | 178.30M |
| Capital Expenditure | -771.00K | -209.00K | -78.00K | -437.00K | -3.81M | - | -47.36M | -41.43M | -400.00K | -506.00K |
| Free Cash Flow | -16.82M | -17.86M | -29.11M | -39.58M | -87.24M | - | -253.82M | -195.61M | -117.72M | -136.51M |
| Net Change in Cash | - | - | - | - | - | - | -541.08M | 95.07M | -117.57M | 41.79M |
| Share Buybacks | 4.00K | 0 | 0 | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | 41.7% | 40.6% | -47.7% | -13.7% | -15.5% | -40.3% | -76.5% | -98.0% | -117.2% | -146.1% |
| ROCE % | - | 431.5% | -30.2% | -14.2% | -13.1% | -31.8% | -55.6% | -63.4% | -60.3% | -76.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 31.69% | 19.92M | $1.99B |
| 2 | Blackrock Inc. | 6.58% | 4.14M | $413.00M |
| 3 | Price (T.Rowe) Associates Inc | 5.17% | 3.25M | $324.44M |
| 4 | State Street Corporation | 3.85% | 2.42M | $241.63M |
| 5 | Goldman Sachs Group Inc | 3.69% | 2.32M | $231.30M |
| 6 | Vanguard Capital Management LLC | 2.87% | 1.80M | $180.23M |
| 7 | Braidwell LP | 2.84% | 1.79M | $178.50M |
| 8 | Jupiter Topco LLC | 2.43% | 1.53M | $152.40M |
| 9 | RTW Investments LP | 2.37% | 1.49M | $148.60M |
| 10 | Boxer Capital Management, LLC | 2.35% | 1.48M | $147.57M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KOD
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPb0RJVmZ1aW9zQ3kyX05lNkUtdDdiOEdkUzMyUFl3UGhMT3FoUlFpV1k1a0VqdEZ5V00yYjNOSE9fcHU1dEVlZTFpNXN5c0E1dlU4eTNvbk56dnU3TGZkWUMzNlF5VERBTnJvdjF3SmUyd1puaXdQRmxManlNRmVjVUpuaDdjdmswbjlrbF…
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNSVZ1LVZvVlRSUTloNjU1N216SHdodWl2TEktdHlRTi03VmVFZnBVMFd3akRrYS1mSUg4TWYwYTJiTGdzczJYVW9sX1JtQzFVMVFFWVBqOF9YOENnZTdKaVVwRTNHT0lONzJjemVEX2hMNzZVS25jZkF3WmJwZFpCeVJrdlhpVDd3ZGR6aD…
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - TradingView
<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxOTEo3WlYzZ2pTYVZXTzFaUUp5dHRPb2FDUW9Sa2l2QmVEbHUtYkg0eXp6RTQwMGRIX0NQVm5NUVZZcE5TVC1Za0NaLWp5WmJOcUdJeUpHN0hQTTc5RFV4a2tHdVdIQV9NTGZtLV9RQ181NWJZa0RmaUJXNkxQdzl0dHVUblVkSkNyRHY5bU…
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOLVZhTGxjRFRGNTRTVTVMQklOeHVpNVFyTzlUVXdsY19DaGRiZEJfQzZ4SXVoVENjMUZ1bW9sYlVZbVFzUGowVE4zelJ0WGp1YUtvdVB5cHZuVEN2dndNUkxERW9Xdnp0QjRYLUJEbGtIbXc0NFhyalpiZEl6NDcybmczblZCaHpNU2k4OH…
Stocks making the biggest moves midday: MongoDB, Boeing, Kodiak Sciences, Roblox, Nvidia & more - CNBC
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPdGpZSG50WmlRYmdoXzZTMWVZZk5mVXpKVlRlNmxqZDZDSm9UQXpCRGlOamJINi13SkJ1aUZxSGd5TjVMYzM3YlhDMFhlb2gxYnBWeWJSMWhDckxnaUd3bzN6ZHMwNE5CbzBGeGhSU1BkMGZhT3dnblNTcDRldGkzTGNIUEprMm1qR0d0NV…
KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street - Timothy Sykes
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE1jaEtQNEh6cjVJMlhBS21mUEdCNnVlT19jQnVjbkVoSFhMVU9KUlotQUJ0LUw0SnczbWJ6UlJlNHpjVURXZnNidWZHdjEzcldKOXRuRk1rRVpQYjdrQ1dQRDA5bHNscEpsWUNQbFlpM2pXQURTYWJjWWNMMnJsQ2c?oc=5" target="_bla…
KOD — Frequently Asked Questions
What is the current share price of Kodiak Sciences Inc. (KOD)?
As of 2026-10-22 16:30 PDT, Kodiak Sciences Inc. (KOD) trades at $85.78 on NasdaqGM. Its 52-week range is $8.55 to $99.87.
What is the market capitalisation of KOD?
Kodiak Sciences Inc. (KOD) has a market capitalisation of $5.39B on NasdaqGM.
What is the P/E ratio of KOD?
KOD trades at a trailing price-to-earnings (P/E) ratio of -20.47. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 33.58.
Is KOD a good stock to buy?
This page provides a data-driven analysis of Kodiak Sciences Inc. (KOD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.